Purinergic signaling in Parkinson's disease. Relevance for treatment

Neuropharmacology

Volumn 104, Issue , 2016, Pages 161-168

  Navarro, Gemma ^a,b   Borroto Escuela, Dasiel O ^c,d   Fuxe, Kjell ^c   Franco, Rafael ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF URBINO   (Italy)

Author keywords

Adenosine receptor antagonist; Adenosine receptors; ATP receptors; GPCR heteromer; Parkinson's disease

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ALPHA SYNUCLEIN; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; ISTRADEFYLLINE; LEVODOPA; PRELADENANT; PURINERGIC P2X1 RECEPTOR; PURINERGIC RECEPTOR; VIPADENANT; 2-(2-FURANYL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)-1-PIPERAZINYL)ETHYL)-7H-PYRAZOLO(4,3-E)(1,2,4)TRIAZOLO(1,5-C)PYRIMIDINE-5-AMINE; ADENOSINE A2 RECEPTOR ANTAGONIST; PURINE DERIVATIVE; PURINE NUCLEOTIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

BASAL GANGLION; CALCIUM CURRENT; CALCIUM SIGNALING; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DYSKINESIA; HUMAN; LEWY BODY; MONOTHERAPY; MOTOR CONTROL; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BASAL GANGLIA; CORPUS STRIATUM; HUMANS; PARKINSON DISEASE; PURINE NUCLEOTIDES; PURINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84938631250     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.07.024     Document Type: Review

References (128)

1. L.F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons Pharmacol. Rev. 55 2003 509 550
2. S. Amadio, C. Montilli, B. Picconi, P. Calabresi, and C. Volonte Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: an immunohistological study Purinergic Signal 3 2007 389 398
3. N.E. Anden, A. Carlsson, A. Dahlstroem, K. Fuxe, N.A. Hillarp, and K. Larsson Demonstration and mapping out of nigro-Neostriatal dopamine neurons Life Sci. 3 1964 523 530
4. T. Antonelli, K. Fuxe, L. Agnati, E. Mazzoni, S. Tanganelli, M.C. Tomasini, and L. Ferraro Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias J. Neurol. Sci. 248 2006 16 22
5. M.T. Armentero, A. Pinna, S. Ferre, J.L. Lanciego, C.E. Muller, and R. Franco Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease Pharmacol. Ther. 132 2011 280 299
6. C. Bergson, R. Levenson, P.S. Goldman-Rakic, and M.S. Lidow Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling Trends Pharmacol. Sci. 24 2003 486 492
7. R.G. Bhushan, S.K. Sharma, Z. Xie, D.J. Daniels, and P.S. Portoghese A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 47 2004 2969 2972
8. W. Birkmayer, and O. Hornykiewicz The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis Arch. Psychiatr. Nervenkr Z Gesamte Neurol. Psychiatr. 203 1962 560 574
9. W. Birkmayer, and O. Hornykiewicz Additional experimental studies on L-dopa in Parkinson's syndrome and Reserpine parkinsonism Arch. Psychiatr. Nervenkr 206 1964 367 381
10. J. Bonaventura, A.J. Rico, E. Moreno, S. Sierra, M. Sanchez, N. Luquin, D. Farre, C.E. Muller, E. Martinez-Pinilla, A. Cortes, J. Mallol, M.T. Armentero, A. Pinna, E.I. Canela, C. Lluis, P.J. McCormick, J.L. Lanciego, V. Casado, and R. Franco L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus Neuropharmacology 79 2014 90 100
11. D.O. Borroto-Escuela, W. Romero-Fernandez, A.O. Tarakanov, M. Gomez-Soler, F. Corrales, D. Marcellino, M. Narvaez, M. Frankowska, M. Flajolet, N. Heintz, L.F. Agnati, F. Ciruela, and K. Fuxe Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices Biochem. Biophys. Res. Commun. 402 2010 801 807
12. D.O. Borroto-Escuela, W. Romero-Fernandez, A.O. Tarakanov, F. Ciruela, L.F. Agnati, and K. Fuxe On the existence of a possible A2A-D2-beta-Arrestin2 complex: a2A agonist modulation of D2 agonist-induced beta-arrestin2 recruitment J. Mol. Biol. 406 2011 687 699
13. D.O. Borroto-Escuela, A.O. Tarakanov, D. Guidolin, F. Ciruela, L.F. Agnati, and K. Fuxe Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration IUBMB Life 63 2011 463 472
14. D.O. Borroto-Escuela, M. Flajolet, L.F. Agnati, P. Greengard, and K. Fuxe Bioluminescence resonance energy transfer methods to study G protein-coupled receptor-receptor tyrosine kinase heteroreceptor complexes Methods Cell Biol. 117 2013 141 164
15. D.O. Borroto-Escuela, W. Romero-Fernandez, P. Garriga, F. Ciruela, M. Narvaez, A.O. Tarakanov, M. Palkovits, L.F. Agnati, and K. Fuxe G protein-coupled receptor heterodimerization in the brain Methods Enzymol. 521 2013 281 294
16. D.O. Borroto-Escuela, I. Brito, W. Romero-Fernandez, M. Di Palma, J. Oflijan, K. Skieterska, J. Duchou, K. Van Craenenbroeck, D. Suarez-Boomgaard, A. Rivera, D. Guidolin, L.F. Agnati, and K. Fuxe The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components Int. J. Mol. Sci. 15 2014 8570 8590
17. D.O. Borroto-Escuela, I. Brito, M. Di Palma, A. Jiménez-Beristain, M. Narvaez, F. Corrales, M. Pita-Rodríguez, S. Sartini, P. Ambrogini, D. Lattanzi, R. Cuppini, L.F. Agnati, and K. Fuxe On the role of the balance of GPCR Homo/Heteroreceptor complexes in the brain J. Adv. Neurosci. Res. 2 2015 36 44
18. G. Burnstock Historical review: ATP as a neurotransmitter Trends Pharmacol. Sci. 27 2006 166 176
19. G. Burnstock Purinergic signalling: pathophysiology and therapeutic potential Keio J. Med. 62 2013 63 73
20. M. Canals, J. Burgueno, D. Marcellino, N. Cabello, E.I. Canela, J. Mallol, L. Agnati, S. Ferre, M. Bouvier, K. Fuxe, F. Ciruela, C. Lluis, and R. Franco Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J. Neurochem. 88 2004 726 734
21. A. Carlsson The occurrence, distribution and physiological role of catecholamines in the nervous system Pharmacol. Rev. 11 1959 490 493
22. M.R. Carmo, A.P. Menezes, A.C. Nunes, A. Pliassova, A.P. Rolo, C.M. Palmeira, R.A. Cunha, P.M. Canas, and G.M. Andrade The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis Neuropharmacology 81 2014 142 152
23. T.N. Chase, A.C. Woods, and G.A. Glaubiger Parkinson disease treated with a suspected dopamine receptor agonist Arch. Neurol. 30 1974 383 386
24. F.B. Chekeni, M.R. Elliott, J.K. Sandilos, S.F. Walk, J.M. Kinchen, E.R. Lazarowski, A.J. Armstrong, S. Penuela, D.W. Laird, G.S. Salvesen, B.E. Isakson, D.A. Bayliss, and K.S. Ravichandran Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis Nature 467 2010 863 867
25. F. Ciruela, V. Casado, R.J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N. Rebola, S.R. Goldberg, J. Mallol, A. Cortes, E.I. Canela, J.F. Lopez-Gimenez, G. Milligan, C. Lluis, R.A. Cunha, S. Ferre, and R. Franco Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers J. Neurosci. 26 2006 2080 2087
26. E. Coppi, F. Pedata, and A.J. Gibb P2Y1 receptor modulation of Ca2+-activated K+ currents in medium-sized neurons from neonatal rat striatal slices J. Neurophysiol. 107 2012 1009 1021
27. H. Corrodi, K. Fuxe, and U. Ungerstedt Evidence for a new type of dopamine receptor stimulating agent J. Pharm. Pharmacol. 23 1971 989 991
28. F. Corti, L. Cellai, A. Melani, C. Donati, P. Bruni, and F. Pedata Adenosine is present in rat brain synaptic vesicles Neuroreport 24 2013 982 987
29. G.C. Cotzias, M.H. Van Woert, and L.M. Schiffer Aromatic amino acids and modification of parkinsonism N. Engl. J. Med. 276 1967 374 379
30. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene Modification of Parkinsonism-chronic treatment with L-dopa N. Engl. J. Med. 280 1969 337 345
31. G. Dahl, and K.J. Muller Innexin and pannexin channels and their signaling FEBS Lett. 588 2014 1396 1402
32. A. Dahlstroem, and K. Fuxe Evidence for the existence of monoamine-containing neurons in the Central nervous system. I. Demonstration of monoamines in the cell bodies of brain Stem neurons Acta Physiol. Scand. Suppl. Suppl. 232 1964 231 255
33. A. Dalpiaz, B. Cacciari, C.B. Vicentini, F. Bortolotti, G. Spalluto, S. Federico, B. Pavan, F. Vincenzi, P.A. Borea, and K. Varani A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach Mol. Pharm. 9 2012 591 604
34. D.J. Daniels, A. Kulkarni, Z. Xie, R.G. Bhushan, and P.S. Portoghese A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes J. Med. Chem. 48 2005 1713 1716
35. F.F. De-Miguel, and K. Fuxe Extrasynaptic neurotransmission as a way of modulating neuronal functions Front. Physiol. 3 2012 16
36. A. Del Arco, G. Segovia, K. Fuxe, and F. Mora Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions? J. Neurochem. 85 2003 23 33
37. R. Dungo, and E.D. Deeks Istradefylline: first global approval Drugs 73 2013 875 882
38. F.A. Edwards, A.J. Gibb, and D. Colquhoun ATP receptor-mediated synaptic currents in the central nervous system Nature 359 1992 144 147
39. H. Ehringer, and O. Hornykiewicz Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin. Wochenschr 38 1960 1236 1239
40. M. Flajolet, Z. Wang, M. Futter, W. Shen, N. Nuangchamnong, J. Bendor, I. Wallach, A.C. Nairn, D.J. Surmeier, and P. Greengard FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity Nat. Neurosci. 11 2008 1402 1409
41. R. Franco G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter Br. J. Pharmacol. 158 2009 23 31
42. R. Franco, S. Ferre, L. Agnati, M. Torvinen, S. Gines, J. Hillion, V. Casado, P. Lledo, M. Zoli, C. Lluis, and K. Fuxe Evidence for adenosine/dopamine receptor interactions: indications for heteromerization Neuropsychopharmacology 23 2000 S50 S59
43. H. Franke, and P. Illes Involvement of P2 receptors in the growth and survival of neurons in the CNS Pharmacol. Ther. 109 2006 297 324
44. B.B. Fredholm, K. Fuxe, and L. Agnati Effect of some phosphodiesterase inhibitors on central dopamine mechanisms Eur. J. Pharmacol. 38 1976 31 38
45. K. Fuxe Evidence for the existence of monoamine neurons in the central nervous system. Iv. Distribution of monoamine nerve terminals in the central nervous system Acta Physiol. Scand. Suppl. 247 1965 237
46. K. Fuxe Dopamine receptor agonists in brain research and as therapeutic agents Trends Neurosci. 2 1979 1 4
47. K. Fuxe, and U. Ungerstedt Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists Med. Biol. 52 1974 48 54
48. K. Fuxe, and N.E. Anden Studies on central monoamine neurons with special reference to the nigro-striatal dopamine neuron systems E. Costa, L.J. Cote, M.D. Yahr, Biochemistry and Pharmacology of the Basal Ganglia 1966 Raven Press New York 123 129
49. K. Fuxe, L.F. Agnati, F. Benfenati, M. Celani, I. Zini, M. Zoli, and V. Mutt Evidence for the existence of receptor-receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides J. Neural Transm. Suppl. 18 1983 165 179
50. K. Fuxe, S. Ferre, P. Snaprud, G. von Euler, B. Johansson, and B. Fredholm Antagonistic A2A/D2 receptor interactions in the striatum as a basis for adenosine - dopamine interactions for the central nervous system Drug Dev. Res. 28 1993 374 380
51. K. Fuxe, S. Ferre, M. Zoli, and L.F. Agnati Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia Brain Res. Brain Res. Rev. 26 1998 258 273
52. K. Fuxe, P. Manger, S. Genedani, and L. Agnati The nigrostriatal DA pathway and Parkinson's disease J. Neural Transm. Suppl. 2006 71 83
53. K. Fuxe, S. Ferre, S. Genedani, R. Franco, and L.F. Agnati Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function Physiol. Behav. 92 2007 210 217
54. K. Fuxe, D. Marcellino, S. Genedani, and L. Agnati Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease Mov. Disord. 22 2007 1990 2017
55. K. Fuxe, D. Marcellino, D. Guidolin, A.S. Woods, and L. Agnati Brain receptor mosaics and their intramembrane receptor-receptor interactions: molecular integration in transmission and novel targets for drug development J. Acupunct. Meridian Stud. 2 2009 1 25
56. K. Fuxe, A.B. Dahlstrom, G. Jonsson, D. Marcellino, M. Guescini, M. Dam, P. Manger, and L. Agnati The discovery of central monoamine neurons gave volume transmission to the wired brain Prog. Neurobiol. 90 2010 82 100
57. K. Fuxe, D. Marcellino, D.O. Borroto-Escuela, M. Guescini, V. Fernandez-Duenas, S. Tanganelli, A. Rivera, F. Ciruela, and L.F. Agnati Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders CNS Neurosci. Ther. 16 2010 e18 42
58. K. Fuxe, D.O. Borroto-Escuela, W. Romero-Fernandez, Z. Diaz-Cabiale, A. Rivera, L. Ferraro, S. Tanganelli, A.O. Tarakanov, P. Garriga, J.A. Narvaez, F. Ciruela, M. Guescini, and L.F. Agnati Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks Front. Physiol. 3 2012 136
59. K. Fuxe, D.O. Borroto-Escuela, A. Tarakanov, R. Romero Fernandez, P. Manger, A. Rivera, K. van Craenenbroeck, K. Skieterska, Z. Diaz-Cabiale, M. Filip, L. Ferraro, S. Tanganelli, D. Guidolin, S. Cullheim, M. Perez de la Mora, and L.F. Agnati Understanding the balance and integration of volume and synaptic transmission. Relevance for psychiatry Neurology, Psychiatry Brain Res. 19 2013 141 158
60. K. Fuxe, D.O. Borroto-Escuela, W. Romero-Fernandez, M. Palkovits, A.O. Tarakanov, F. Ciruela, and L.F. Agnati Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field Neuropsychopharmacology 39 2014 131 155
61. K. Fuxe, D. Guidolin, L.F. Agnati, and D.O. Borroto-Escuela Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease Expert Opin. Ther. Targets 19 2015 377 398
62. M. Gan, S. Moussaud, P. Jiang, and P.J. McLean Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction Neurobiol. Aging 36 2015 1209 1220
63. R.J. Gillespie, S.J. Bamford, R. Botting, M. Comer, S. Denny, S. Gaur, M. Griffin, A.M. Jordan, A.R. Knight, J. Lerpiniere, S. Leonardi, S. Lightowler, S. McAteer, A. Merrett, A. Misra, A. Padfield, M. Reece, M. Saadi, D.L. Selwood, G.C. Stratton, D. Surry, R. Todd, X. Tong, V. Ruston, R. Upton, and S.M. Weiss Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines J. Med. Chem. 52 2009 33 47
64. S. Gines, J. Hillion, M. Torvinen, S. Le Crom, V. Casado, E.I. Canela, S. Rondin, J.Y. Lew, S. Watson, M. Zoli, L.F. Agnati, P. Verniera, C. Lluis, S. Ferre, K. Fuxe, and R. Franco Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes Proc. Natl. Acad. Sci. U. S. A. 97 2000 8606 8611
65. W. Guo, E. Urizar, M. Kralikova, J.C. Mobarec, L. Shi, M. Filizola, and J.A. Javitch Dopamine D2 receptors form higher order oligomers at physiological expression levels EMBO J. 27 2008 2293 2304
66. S. Gyoneva, L. Shapiro, C. Lazo, E. Garnier-Amblard, Y. Smith, G.W. Miller, and S.F. Traynelis Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease Neurobiol. Dis. 67 2014 191 202
67. M.M. Halassa, C. Florian, T. Fellin, J.R. Munoz, S.Y. Lee, T. Abel, P.G. Haydon, and M.G. Frank Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss Neuron 61 2009 213 219
68. A. Hasbi, T. Fan, M. Alijaniaram, T. Nguyen, M.L. Perreault, B.F. O'Dowd, and S.R. George Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth Proc. Natl. Acad. Sci. U. S. A. 106 2009 21377 21382
69. R.A. Hauser Future treatments for Parkinson's disease: surfing the PD pipeline Int. J. Neurosci. 121 Suppl. 2 2011 53 62
70. J. Hillion, M. Canals, M. Torvinen, V. Casado, R. Scott, A. Terasmaa, A. Hansson, S. Watson, M.E. Olah, J. Mallol, E.I. Canela, M. Zoli, L.F. Agnati, C.F. Ibanez, C. Lluis, R. Franco, S. Ferre, and K. Fuxe Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors J. Biol. Chem. 277 2002 18091 18097
71. D.J. Hines, and P.G. Haydon Astrocytic adenosine: from synapses to psychiatric disorders Philos. Trans. R. Soc. Lond B Biol. Sci. 369 2014 20130594
72. S.A. Hitchcock Blood-brain barrier permeability considerations for CNS-targeted compound library design Curr. Opin. Chem. Biol. 12 2008 318 323
73. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, S. Fredduzzi, M.E. Cohen-Williams, G.A. Higgins, F. Impagnatiello, E. Nicolussi, L.E. Parra, C. Foster, Y. Zhai, B.R. Neustadt, A.W. Stamford, E.M. Parker, A. Reggiani, and J.C. Hunter Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 330 2009 294 303
74. L. Hove-Madsen, C. Prat-Vidal, A. Llach, F. Ciruela, V. Casado, C. Lluis, A. Bayes-Genis, J. Cinca, and R. Franco Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release Cardiovasc Res. 72 2006 292 302
75. D.G. Jackson, J. Wang, R.W. Keane, E. Scemes, and G. Dahl ATP and potassium ions: a deadly combination for astrocytes Sci. Rep. 4 2014 4576
76. P. Jenner, A.R. Taylor, and D.B. Campbell Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent J. Pharm. Pharmacol. 25 1973 749 750
77. H. Kittner, U. Krugel, and P. Illes The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats Neuroscience 102 2001 241 243
78. B.P. Klyuch, N. Dale, and M.J. Wall Deletion of ecto-5'-nucleotidase (CD73) reveals direct action potential-dependent adenosine release J. Neurosci. 32 2012 3842 3847
79. U. Krugel, H. Kittner, H. Franke, and P. Illes Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo Neuropharmacology 40 2001 1084 1093
80. U. Krugel, H. Kittner, and P. Illes Mechanisms of adenosine 5'-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo Synapse 39 2001 222 232
81. S.P. Lee, B.F. O'Dowd, and S.R. George Homo- and hetero-oligomerization of G protein-coupled receptors Life Sci. 74 2003 173 180
82. M.S. Lidow Calcium signaling dysfunction in schizophrenia: a unifying approach Brain Res. Brain Res. Rev. 43 2003 70 84
83. H. Liu, X. Han, Y. Li, H. Zou, and A. Xie Association of P2X7 receptor gene polymorphisms with sporadic Parkinson's disease in a Han Chinese population Neurosci. Lett. 546 2013 42 45
84. A. Llach, C.E. Molina, C. Prat-Vidal, J. Fernandes, V. Casado, F. Ciruela, C. Lluis, R. Franco, J. Cinca, and L. Hove-Madsen Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors Eur. Heart J. 32 2011 721 729
85. S. Locovei, J. Wang, and G. Dahl Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium FEBS Lett. 580 2006 239 244
86. S. Locovei, E. Scemes, F. Qiu, D.C. Spray, and G. Dahl Pannexin1 is part of the pore forming unit of the P2X(7) receptor death complex FEBS Lett. 581 2007 483 488
87. D. Lovatt, Q. Xu, W. Liu, T. Takano, N.A. Smith, J. Schnermann, K. Tieu, and M. Nedergaard Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity Proc. Natl. Acad. Sci. U. S. A. 109 2012 6265 6270
88. D. Marcellino, D. Suarez-Boomgaard, M.D. Sanchez-Reina, J.A. Aguirre, T. Yoshitake, S. Yoshitake, B. Hagman, J. Kehr, L.F. Agnati, K. Fuxe, and A. Rivera On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079 J. Neural Transm. 117 2010 681 687
89. F. Martinon, K. Burns, and J. Tschopp The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol. Cell 10 2002 417 426
90. L. Minghetti, M.A. Ajmone-Cat, M.A. De Berardinis, and R. De Simone Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation Brain Res. Brain Res. Rev. 48 2005 251 256
91. L. Minghetti, A. Greco, R.L. Potenza, A. Pezzola, D. Blum, K. Bantubungi, and P. Popoli Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration J. Neuropathol. Exp. Neurol. 66 2007 363 371
92. G. Navarro, M.S. Aymerich, D. Marcellino, A. Cortes, V. Casado, J. Mallol, E.I. Canela, L. Agnati, A.S. Woods, K. Fuxe, C. Lluis, J.L. Lanciego, S. Ferre, and R. Franco Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors J. Biol. Chem. 284 2009 28058 28068
93. G. Navarro, S. Ferre, A. Cordomi, E. Moreno, J. Mallol, V. Casado, A. Cortes, H. Hoffmann, J. Ortiz, E.I. Canela, C. Lluis, L. Pardo, R. Franco, and A.S. Woods Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers J. Biol. Chem. 285 2010 27346 27359
94. B.R. Neustadt, J. Hao, N. Lindo, W.J. Greenlee, A.W. Stamford, D. Tulshian, E. Ongini, J. Hunter, A. Monopoli, R. Bertorelli, C. Foster, L. Arik, J. Lachowicz, K. Ng, and K.I. Feng Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines Bioorg Med. Chem. Lett. 17 2007 1376 1380
95. E.A. Newman Glial cell inhibition of neurons by release of ATP J. Neurosci. 23 2003 1659 1666
96. N. Nishino, N. Kitamura, T. Hashimoto, and C. Tanaka Transmembrane signalling systems in the brain of patients with Parkinson's disease Rev. Neurosci. 4 1993 213 222
97. O. Pascual, K.B. Casper, C. Kubera, J. Zhang, R. Revilla-Sanchez, J.Y. Sul, H. Takano, S.J. Moss, K. McCarthy, and P.G. Haydon Astrocytic purinergic signaling coordinates synaptic networks Science 310 2005 113 116
98. F. Pedata, A.M. Pugliese, A. Melani, and M. Gianfriddo A2A receptors in neuroprotection of dopaminergic neurons Neurology 61 2003 S49 S50
99. L. Peng, R. Huang, A.C. Yu, K.Y. Fung, M.P. Rathbone, and L. Hertz Nucleoside transporter expression and function in cultured mouse astrocytes Glia 52 2005 25 35
100. J.P. Petzer, S. Steyn, K.P. Castagnoli, J.F. Chen, M.A. Schwarzschild, C.J. Van der Schyf, and N. Castagnoli Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists Bioorg Med. Chem. 11 2003 1299 1310
101. B. Picconi, F. Gardoni, D. Centonze, D. Mauceri, M.A. Cenci, G. Bernardi, P. Calabresi, and M. Di Luca Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism J. Neurosci. 24 2004 5283 5291
102. M. Pierri, E. Vaudano, T. Sager, and U. Englund KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacology 48 2005 517 524
103. A. Pinna Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued CNS Drugs 28 2014 455 474
104. A. Pinna, and M. Morelli A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: the case of adenosine A(2A) receptor antagonists Neurotox. Res. 25 2014 392 401
105. A. Pinna, J. Bonaventura, D. Farre, M. Sanchez, N. Simola, J. Mallol, C. Lluis, G. Costa, Y. Baqi, C.E. Muller, A. Cortes, P. McCormick, E.I. Canela, E. Martinez-Pinilla, J.L. Lanciego, V. Casado, M.T. Armentero, and R. Franco L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies Exp. Neurol. 253 2014 180 191
106. J. Pintor, M.A. Diaz-Rey, and M.T. Miras-Portugal Ap4A and ADP-beta-S binding to P2 purinoceptors present on rat brain synaptic terminals Br. J. Pharmacol. 108 1993 1094 1099
107. W. Poewe, P. Mahlknecht, and J. Jankovic Emerging therapies for Parkinson's disease Curr. Opin. Neurol. 25 2012 448 459
108. F. Qiu, and G. Dahl A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP Am. J. Physiol. Cell Physiol. 296 2009 C250 C255
109. F. Qiu, J. Wang, and G. Dahl Alanine substitution scanning of pannexin1 reveals amino acid residues mediating ATP sensitivity Purinergic Signal 8 2012 81 90
110. A. Ramirez-Zamora, and E. Molho Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions Expert Rev. Neurother. 14 2014 93 103
111. A.J. Rashid, C.H. So, M.M. Kong, T. Furtak, M. El-Ghundi, R. Cheng, B.F. O'Dowd, and S.R. George D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum Proc. Natl. Acad. Sci. U. S. A. 104 2007 654 659
112. N. Rebola, A.P. Simoes, P.M. Canas, A.R. Tome, G.M. Andrade, C.E. Barry, P.M. Agostinho, M.A. Lynch, and R.A. Cunha Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction J. Neurochem. 117 2011 100 111
113. F. Rodriguez-Pascual, R. Cortes, M. Torres, J.M. Palacios, and M.T. Miras-Portugal Distribution of [3H]diadenosine tetraphosphate binding sites in rat brain Neuroscience 77 1997 247 255
114. A. Sato, Y. Arimura, Y. Manago, K. Nishikawa, K. Aoki, E. Wada, Y. Suzuki, H. Osaka, R. Setsuie, M. Sakurai, T. Amano, S. Aoki, K. Wada, and M. Noda Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells J. Cell Physiol. 209 2006 172 182
115. J. Saura, E. Angulo, A. Ejarque, V. Casado, J.M. Tusell, R. Moratalla, J.F. Chen, M.A. Schwarzschild, C. Lluis, R. Franco, and J. Serratosa Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia J. Neurochem. 95 2005 919 929
116. M.A. Schwarzschild, L. Agnati, K. Fuxe, J.F. Chen, and M. Morelli Targeting adenosine A2A receptors in Parkinson's disease Trends Neurosci. 29 2006 647 654
117. M.V. Sitkovsky, S. Hatfield, R. Abbott, B. Belikoff, D. Lukashev, and A. Ohta Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists Cancer Immunol. Res. 2 2014 598 605
118. A. Soriano, R. Ventura, A. Molero, R. Hoen, V. Casado, A. Cortes, F. Fanelli, F. Albericio, C. Lluis, R. Franco, and M. Royo Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers J. Med. Chem. 52 2009 5590 5602
119. A. Stossel, M. Schlenk, S. Hinz, P. Kuppers, J. Heer, M. Gutschow, and C.E. Muller Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones J. Med. Chem. 56 2013 4580 4596
120. P. Trifilieff, M.L. Rives, E. Urizar, R.A. Piskorowski, H.D. Vishwasrao, J. Castrillon, C. Schmauss, M. Slattman, M. Gullberg, and J.A. Javitch Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum Biotechniques 51 2011 111 118
121. U. Ungerstedt Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system Acta Physiol. Scand. Suppl. 367 1971 69 93
122. Y. Wang, C.F. Chang, M. Morales, Y.H. Chiang, B.K. Harvey, T.P. Su, L.I. Tsao, S. Chen, and C. Thiemermann Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain J. Neurosci. 23 2003 7958 7965
123. A.S. Woods, D. Marcellino, S.N. Jackson, R. Franco, S. Ferre, L.F. Agnati, and K. Fuxe How calmodulin interacts with the adenosine A(2A) and the dopamine D(2) receptors J. Proteome Res. 7 2008 3428 3434
124. K. Yoshioka, O. Saitoh, and H. Nakata Heteromeric association creates a P2Y-like adenosine receptor Proc. Natl. Acad. Sci. U. S. A. 98 2001 7617 7622
125. Y.X. Zhang, H. Yamashita, T. Ohshita, N. Sawamoto, and S. Nakamura ATP increases extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum Brain Res. 691 1995 205 212
126. Z. Zhang, G. Chen, W. Zhou, A. Song, T. Xu, Q. Luo, W. Wang, X.S. Gu, and S. Duan Regulated ATP release from astrocytes through lysosome exocytosis Nat. Cell Biol. 9 2007 945 953
127. S. Zhang, C. Xie, Q. Wang, and Z. Liu Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats Sci. Rep. 4 2014 6811
128. H. Zimmermann Extracellular metabolism of ATP and other nucleotides Naunyn Schmiedeb. Arch. Pharmacol. 362 2000 299 309